H2 Equity Partners (“H2”) is pleased to announce that it has successfully divested of its holding in GBUK Group Limited (“GBUK” or the “Company”) to A&M Capital Europe LLP (“AMCE”), a London-based middle-market private equity investment firm with €650 million of assets under management.
GBUK is a market leading provider of acute care medical devices across the Enteral, Critical Care, Vascular and Patient Handling sectors. The Group supports a range of healthcare professionals and patients in over 45 countries worldwide and utilises its R&D and product development capability to continually expand and develop its range to meet clinical needs of patients.
H2 acquired a majority stake in 2015 from the Founder and worked alongside the GBUK management team to support the continued growth and development of the business. Since acquisition GBUK has evolved to become an own-product focused business with an extensive portfolio of critical products with international reach. During H2’s ownership sales have more than quadrupled to £80 million per annum and 4 acquisitions were completed during the last eight years. GBUK is well positioned to continue on its exciting growth journey.
The partnership with AMCE is expected to enable GBUK to enhance patient care further and drive the innovation required to support the evolving needs of patients and healthcare providers. Leveraging GBUK’s intimate understanding of patient needs, new product development expertise and global supply-chain capabilities, the Company is well-positioned to continue delivering on this mission and support patients globally.
H2 Equity Partners were supported by Piper Sandler, Squire Patton Boggs, PWC and Kearney.
